Evolution of the proportion of patients treated with anticoagulants, with antiplatelet therapy alone or no antithrombotic therapy among patients with NVAF with CHA2DS2-VASc ≥2
| April 2012 % (95% CI) | April 2013 % (95% CI) | April 2014 % (95% CI) | April 2015 % (95% CI) | January 2016 % (95% CI) | |
| Anticoagulation | 50.2 (49.8 to 50.5) | 53.2 (52.8 to 53.5) | 57.5 (57.1 to 57.9) | 62.9 (62.5 to 63.3) | 66.9 (66.5 to 67.3) |
| Antiplatelet therapy alone | 34.2 (33.9 to 34.5) | 31.2 (30.8 to 31.5) | 27.7 (27.3 to 28.0) | 21.8 (21.5 to 22.2) | 17.4 (17.1 to 17.8) |
| No antithrombotic therapy | 15.6 (15.4 to 15.9) | 15.7 (15.4 to 15.9) | 14.8 (14.6 to 15.1) | 15.3 (15.0 to 15.6) | 15.7 (15.4 to 16.0) |